Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. (UH3-India)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03638622|
Recruitment Status : Completed
First Posted : August 20, 2018
Results First Posted : February 21, 2021
Last Update Posted : February 21, 2021
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Oral Cancer||Combination Product: Photodynamic Therapy||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Trial with single arm|
|Masking:||None (Open Label)|
|Official Title:||Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral|
|Actual Study Start Date :||March 10, 2017|
|Actual Primary Completion Date :||October 12, 2020|
|Actual Study Completion Date :||October 12, 2020|
Experimental: Aminolevulinic acid (ALA) and Photodynamic Therapy (PDT)
Aminolevulinic Acid (ALA) administration, Photodynamic Therapy (PDT) treatment using LED (Light-emitting diode) light source and follow-up.
Combination Product: Photodynamic Therapy
Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
- Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT) [ Time Frame: Up to 2 years ]Histologically confirmed the absence of residual disease at follow-up lesion site biopsy (7 days) and from additional clinical examinations during follow-up visits. The follow-up visits happened approximately once every 3 months after treatment until Institutional Review Board (IRB) approval (October 12, 2020).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||21 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age above 21 years, males or females
- Subject has read and signed a written informed consent form
- Subject is willing to have ALA administered and wait for 2-3 hours
- Subject is willing to receive red light irradiation in the mouth via the fiber probe/applicator and is willing to have the fiber probe/applicator in the mouth for a maximum time of 1 hour
- Subject is willing to allow investigators to take measurements using smart phone imaging before, during and after light treatment
- After the procedure, the subject is willing to avoid spicy, hot, or oily foods for at least 6 hours
- Subject willing to wear full sleeve shirt and full-length garments for couple of hours
- Pregnancy or nursing (ALA is a drug that belongs to FDA pregnancy category C).
- History of photosensitivity diseases (e.g., lupus erythematosus, porphyrias).
- Therapy with any photosensitizing medication, e.g., thiazides (for the treatment of high blood pressure), fluoroquinolones, griseofulvin, or sulfonamides (for the treatment of infections), sulfonylureas (for the treatment of diabetes), phenothiazines (for the treatment of emotional problems), and other medications reported to cause photosensitivity within the last 6 months.
- Subject is unable or unwilling to comply with the study requirements.
- Subject has any conditions or scars within the location of the test sites that may interfere with the treatment or evaluation.
- Allergy to porphyrins or ALA.
- Subject has received laser treatment within 6 months in the area of the treatment.
- Subject is participating in other potentially confounding research, e.g., currently enrolled in a clinical study of any other unapproved investigational drug or device.
- Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study.
- Subject has inadequate organ function.
- Subject has co-morbid systemic illnesses or severe concurrent disease.
- Subject is being treated for vascular disease.
- Subject is an employee of the participating sites directly supervised by the investigator.
- Subject with invasive deep carcinoma evaluated by biopsy.
- Subject is currently being treated for other cancers with medical or radiation therapy.
- Subject has AIDS or other infectious diseases, including tuberculosis, hepatitis or herpetic lesions (oral herpes).
- Subject has oral submucous fibrosis (OSF) resulting in a patient inability to comfortably hold the light applicator in mouth.
- Subject has Human papillomavirus (HPV) positive tumor.
- Subject has the tumor at Oropharynx area.
- We will excludes the patients of the all other oral lesions at sites except: the gingivobuccal sulcus, cheek, floor of the mouth and tongue.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03638622
|J.N. Medical College, Aligarh Muslim University|
|Aligarh, UP, India, 202002|
|Principal Investigator:||Tayyaba Hasan, PhD||Massachusetts General Hospital, Boston|
Documents provided by Tayyaba Hasan,Ph.D., Massachusetts General Hospital:
|Responsible Party:||Tayyaba Hasan,Ph.D., Professor of Dermatology, Massachusetts General Hospital|
|Other Study ID Numbers:||
5UH3CA189901-04 ( U.S. NIH Grant/Contract )
|First Posted:||August 20, 2018 Key Record Dates|
|Results First Posted:||February 21, 2021|
|Last Update Posted:||February 21, 2021|
|Last Verified:||February 2021|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||Yes|
Oral cancer, Photodynamic Therapy, Photosensitizer, ALA
Head and Neck Neoplasms
Neoplasms by Site